Aller au contenu principal
Accès ouvert déclaré 2025 article

The Rs 100 “R+Cu” (resveratrol and copper) anti-cancer magic tablet controversy: Results of online survey among oncologists

0Citations signalées, ce qui n’est pas une note de qualité
11Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : in. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Recently, there has been a lot of interest and controversy regarding the media reporting the impending availability of a Rs 100 nutraceutical to prevent the resurgence of cancer. The institution involved rapidly issued a statement to clarify the facts. We also decided to see the short-term effect of this episode on the practicing oncologist. Here we present the results of this survey. METHODS: A 13-question multiple-choice (MCQ) survey was created using Google Forms and circulated among oncologists via WhatsApp. Responses were collected over three days, and duplicate entries were deleted. Answers from oncologists who were not aware of the controversy were also excluded. In addition, opinions were documented regarding a social media video aimed at reducing misconceptions among the general public, and the views of oncologists who had seen the video were specifically analyzed. RESULTS: A total of 237 out of 240 responders were aware of the controversy and were analyzed. Majority (210/237; 88.6%) of the responders were of the opinion that the initial press release by Tata Memorial Center (TMC) was premature and not necessary resulted in misinterpretation by the media as well as the laypersons. The majority of the oncologists (177/237; 74.7%) also felt that the clarification" statement from TMC was too little, too late. Among the oncologists who had seen the social media video (190/237; 80.2%), more than 90% were of the opinion that it was factually correct, appropriate, and allowed the laypersons to understand the message correctly helping with patient counselling, and that it was not offensive to TMC. CONCLUSION: Healthcare professionals and institutions that are centers of excellence have to be careful when announcing the results of a new potential breakthrough. The press and digital media have a tendency to exaggerate to convert this into breaking news. A rapid response by the institutions will help ensure that the misconception is correctly addressed by facts and references. The use of social media to reach out to laypeople is an effective additional tool to convey the correct message nationwide.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The Rs 100 “R+Cu” (resveratrol and copper) anti-cancer magic tablet controversy: Results of online survey among oncologists
Date Crossref
01/07/2025
Éditeur
Ovid Technologies (Wolters Kluwer Health)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Sirtuins and Resveratrol in MedicineCancer, Lipids, and MetabolismAdvanced Breast Cancer Therapies

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.